Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatinib Combined With Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma Who Failed at Least the First-line Treatment

NCT04586088 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04586088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04586088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatinib Combined With Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma Who Failed at Least the First-line Treatment
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Unknown status
Start date
May 5, 2020
Completion date
September 5, 2023
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy effect, immunotherapy, metastatic nasopharyngeal carcinoma, molecular targeted therapy, nasopharyngeal carcinoma, recurrent nasopharyngeal carcinoma